Cogent Biosciences, Inc.
COGT · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.12 | 0.16 | 0.68 | -0.50 |
| FCF Yield | -6.65% | -9.88% | -7.04% | -4.39% |
| EV / EBITDA | -10.48 | -7.72 | -11.70 | -14.94 |
| Quality | ||||
| ROIC | -34.66% | -31.74% | -26.93% | -22.68% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 0.79 | 0.74 | 0.92 | 0.89 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 18.47% | -10.56% | -16.05% | -21.97% |
| Safety | ||||
| Net Debt / EBITDA | 0.93 | 1.48 | 1.21 | 1.07 |
| Interest Coverage | -240.71 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,293.22 | -1,119.38 | 0.00 | -1,235.63 |